NCT01154816 · OUTCOME

Serum Concentration of Alisertib Prior to the First Day of Administration

Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia · Source last updated 2020-05-13

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

What was measured

Serum concentration of alisertib prior to the first day of administration in nanograms/milliliter.

Analysis population: Of all eligible patients enrolled, 32 provided a prior to the first day of administration sample for analysis.

All patients.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
All Patients	32

Source class 1

Values in ng/ml · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
All Patients	0	0	Not reported	Not reported	Not reported

Complete source fields

classes

denoms

description

Serum concentration of alisertib prior to the first day of administration in nanograms/milliliter.

dispersion Type

Standard Deviation

groups

param Type

MEAN

population Description

Of all eligible patients enrolled, 32 provided a prior to the first day of administration sample for analysis.

reporting Status

POSTED

time Frame

day 1 of protocol therapy

title

Serum Concentration of Alisertib Prior to the First Day of Administration

type

SECONDARY

unit Of Measure

ng/ml

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice